TeraImmune
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
TeraImmune was a Germantown, Maryland biotechnology startup founded in 2016 and headed by Yong Chan Kim, PhD. It developed novel Treg-based cell therapies for autoimmune diseases, combining target-specific receptors with human regulatory T cells — CAR-Treg and TCR-Treg technologies. Its lead candidate TI-168 was a TCR-Treg therapy for Hemophilia A patients with FVIII inhibitors, with an FDA-cleared IND; TI-235 targeted multiple sclerosis.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
TeraImmune is founded in Maryland to develop Treg-based cell therapies.
- NIH grants
TeraImmune wins an NIH SBIR Phase 1 grant and an NHLBI PACT program award supporting cell-manufacturing process development.
- Acquired by Baudax Bio
Baudax Bio (Nasdaq: BXRX) acquires TeraImmune, adding the TI-168 program with its FDA-cleared IND to its portfolio; CEO Gerri Henwood leads the combined entity.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.